Healthcare

Anaphylaxis Treatment Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Anaphylaxis Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Anaphylaxis Treatment Market:

https://www.thebusinessresearchcompany.com/report/anaphylaxis-treatment-global-market-report

According to The Business Research Company’s Anaphylaxis Treatment Global Market Report 2024, The anaphylaxis treatment market size has grown strongly in recent years. It will grow from $5.73 billion in 2023 to $6.15 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing incidence of allergic reactions, wider recognition of anaphylaxis, increased availability of epinephrine auto-injectors, public awareness and education, healthcare professional training.

The anaphylaxis treatment market size is expected to see strong growth in the next few years. It will grow to $7.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to innovation in biologic therapies, customized treatment approaches, global efforts on food safety, patient empowerment and advocacy, enhanced emergency medical services. Major trends in the forecast period include auto-injectors innovation, telemedicine for anaphylaxis management, improved allergen immunotherapy, biometric wearables for allergen detection, collaborations in allergy research.

The rise in the prevalence of food allergies is expected to propel the growth of the anaphylaxis treatment market going forward. Food allergy refers to an immune reaction to proteins in food. Anaphylaxis treatment helps to prevent the progression of life-threatening allergic symptoms involving the skin, mucosal surface, respiratory compromise, hypotension, and end-organ dysfunction. For instance, in January 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2021, 31.8% of adults aged 18 and older reported having eczema, a seasonal allergy, or a food allergy. One-fourth (25.7%) of adults had a seasonal allergy, 6.2% had a food allergy, and 7.3% of individuals had eczema. Therefore, the rise in the prevalence of food allergies is driving the growth of the anaphylaxis treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12105&type=smp

The anaphylaxis treatment market covered in this report is segmented –

1) By Treatment: Epinephrine, Antihistamines, Steroids, Beta-antagonists, Other Treatments

2) By Product: Tablets, Capsules, Other Products

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By Application: Food Allergy, Pollen Allergy, Dust Mites Allergy, Other Applications

Advancement in product development is a key trend gaining popularity in the anaphylaxis treatment market. Major companies operating in the anaphylaxis treatment market are advancing their products to sustain their position in the market. For instance, in April 2022, Aquestive Therapeutics Inc., a US-based pharmaceutical company, received Fast Track designation for AQST-109 for the treatment of severe allergic responses, including anaphylaxis, from the Food and Drug Administration. Aquestive is moving forward with the clinical testing of AQST-109, the first and only orally administered epinephrine product candidate that has demonstrated clinical outcomes equivalent to autoinjectors (such as EpiPen and Auvi-Q) for the treatment of allergic emergencies, including anaphylaxis.

The anaphylaxis treatment market report table of contents includes: